RHHBY

Roche holdings ag spn adr each rep 0.125 g…

0.00 USD

Last updated Dec 3, 03:50 UTC

Yesterday HIGH

$0

Yesterday LOW

$0

52w HIGH

$0

52w LOW

$0

EPS

1

PE

0.00

Overview News Government Trades

Roche holdings ag spn adr each rep 0.125 g… stock is down -100% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70.83% of the previous 28 December’s closed higher than November.

N/A

Stock Exchange

-

Sector

Services

Industry

Personal Services

Headquarters

-

Benzinga Newsdesk

Wed Oct 4, 2023

Roche Group's Genentech Presented Results From The Primary Analysis Of The Ongoing RAINBOWFISH Study, Assessing The Efficacy And Safety Of Evrysdi® In Babies, At The 28th World Muscle Society Congress
Benzinga Newsdesk

Mon Oct 2, 2023

Roche To Present New Key Clinical And Real-World Data At ECTRIMS-ACTRIMS 2023 Showcasing Strength Of Long-Term Outcomes In MS And NMOSD
Vandana Singh

Wed Sep 27, 2023

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY
Upwallstreet

Fri Sep 22, 2023

AI To Revolutionize Clinical Trials And Diagnostics

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving diagnostics.
Vandana Singh

Thu Sep 21, 2023

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.
Benzinga Newsdesk

Tue Sep 12, 2023

TD Cowen Maintains Market Perform on Roche Holding, Lowers Price Target to $40

TD Cowen analyst Steve Scala maintains Roche Holding (OTC:RHHBY) with a Market Perform and lowers the price target from $45 to $40.
Steve Macalbry

Mon Sep 11, 2023

AI Integration In Biotech & Pharma: Companies Positioned To Benefit

The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care. For investors keen on capturing this intersection's potential, several publicly traded companies are making significant strides in embedding AI into their operations.
Vandana Singh

Thu Sep 7, 2023

Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,
Benzinga Newsdesk

Wed Sep 6, 2023

FDA Accepts Roche's Subsidiary Genentech's Application Of Crovalimab For The Treatment Of PNH, A Rare Life-Threatening Blood Condition
Vandana Singh

Fri Sep 1, 2023

Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer

Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a